ArticleCardiovascular and interventional radiology2026
Antitumor Effects of Doxorubicin-Loaded Cellulose Nanoparticles in the Rabbit VX2 Liver Tumor Model.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo evaluate the preclinical efficacy and safety of transarterial chemoembolization (TACE) using doxorubicin-loaded biocompatible cellulose nanoparticles in a rabbit VX2 liver tumor model. MATERIALS AND
methodsFollowing institutional animal care committee approval, 23 rabbits with VX2 liver tumors were randomized into three groups: Group A (n = 9) received doxorubicin-loaded cellulose nanoparticles with ethiodized oil; Group B (n = 9) received doxorubicin with ethiodized oil; and Group C (n = 5) served as untreated controls. Tumor size was monitored via ultrasound for 4 weeks, and serum liver enzymes (aspartate transaminase and alanine transaminase) were measured on days 1, 3, and 7 to assess hepatotoxicity. An additional 10 healthy rabbits were randomized into two groups: Group D (n = 5) received doxorubicin-loaded cellulose nanoparticles with ethiodized oil, and Group E (n = 5) received doxorubicin with ethiodized oil, to measure serum doxorubicin concentrations up to 30 min post-treatment.
resultsGroup A demonstrated significantly slower overall tumor growth compared to Group C (p = 0.005) and slower growth between days 24 and 27 compared to Group B (p = 0.037). Pharmacokinetic analysis showed significantly lower serum doxorubicin levels in Group D than Group E at 2 and 5 min post-delivery (p < 0.05). Hepatotoxicity peaked at 24 h, with significantly lower alanine transaminase levels in Group A compared to Group B (p = 0.025), normalizing by day 7.
conclusionTACE using doxorubicin-loaded cellulose nanoparticles demonstrated promising preclinical efficacy and safety compared to conventional TACE. LEVEL OF EVIDENCE: No level of evidence, Animal Study.
Indexed as
Identifiers
40925976What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.